GILEAD SCIENCES SL

🇪🇸Spain
Ownership
-
Established
1994-01-01
Employees
-
Market Cap
$95.8B
Website
http://www.gilead.com/about/worldwide-operations/europe/spain
Clinical Trials
Related News

Fanconi Syndrome Due to ARVs in HIV-Infected Persons

First Posted Date
2007-07-11
Last Posted Date
2014-03-17
Lead Sponsor
Gilead Sciences
Target Recruit Count
56
Registration Number
NCT00499187
Locations
🇺🇸

University of Indiana, Indianapolis, Indiana, United States

Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection

First Posted Date
2007-07-11
Last Posted Date
2011-08-02
Lead Sponsor
Gilead Sciences
Registration Number
NCT00499720

Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection

Phase 2
Completed
Conditions
HIV Infections
Interventions
Drug: EVG
Drug: RTV
Drug: ARV regimen
First Posted Date
2007-03-08
Last Posted Date
2016-04-25
Lead Sponsor
Gilead Sciences
Target Recruit Count
192
Registration Number
NCT00445146

Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension

Phase 2
Completed
Conditions
Pulmonary Hypertension
First Posted Date
2007-01-18
Last Posted Date
2013-06-17
Lead Sponsor
Gilead Sciences
Target Recruit Count
36
Registration Number
NCT00423592

Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.

Phase 3
Completed
Conditions
Pulmonary Arterial Hypertension
First Posted Date
2007-01-18
Last Posted Date
2009-04-16
Lead Sponsor
Gilead Sciences
Target Recruit Count
186
Registration Number
NCT00423748

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.

Phase 3
Completed
Conditions
Pulmonary Arterial Hypertension
First Posted Date
2007-01-18
Last Posted Date
2009-04-16
Lead Sponsor
Gilead Sciences
Target Recruit Count
186
Registration Number
NCT00423202

Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension

Phase 2
Completed
Conditions
Pulmonary Hypertension
First Posted Date
2007-01-18
Last Posted Date
2012-01-27
Lead Sponsor
Gilead Sciences
Target Recruit Count
54
Registration Number
NCT00424021

Phase I/II Study of hLL1 in Multiple Myeloma

First Posted Date
2007-01-12
Last Posted Date
2021-08-16
Lead Sponsor
Gilead Sciences
Target Recruit Count
25
Registration Number
NCT00421525
Locations
🇺🇸

Winship Cancer Institute, Emory University, Atlanta, Georgia, United States

🇺🇸

Center for Cancer Care, Goshen, Indiana, United States

🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 3 locations

Safety Study of NHL With 90Y-hLL2 IgG

Phase 1
Completed
Conditions
B-cell NHL
Non-Hodgkins Lymphoma
NHL
Interventions
Biological: 90Y-hLL2
First Posted Date
2007-01-12
Last Posted Date
2021-08-16
Lead Sponsor
Gilead Sciences
Target Recruit Count
59
Registration Number
NCT00421395
Locations
🇩🇪

Universitatsklinikum University of Saarland, Homburg/Saar, Germany

🇫🇷

Research Unit 463 INSERM, Nantes, Cedex, France

🇫🇷

Service des Maladies du Sang, Lille, France

and more 2 locations

Ambisome and Management of Culture-negative Neutropenic Fever Unresponsive to Antibiotics

First Posted Date
2007-01-11
Last Posted Date
2011-03-11
Lead Sponsor
Gilead Sciences
Target Recruit Count
20
Registration Number
NCT00421187
Locations
🇬🇷

Gilead Sciences, Athens, Greece

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy